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ABSTRACT 
The present study will outline formulation and the evaluation methods of injectable dosage form. The various initial formulations of 
the developed and those are examined for drug release profile, bioavailability, and clinical effectiveness and for the pilot plant 
studies and production scale-up. The drug that we need should be most convenient and in proper form then only it reaches to the 
desired site of action. This is greatly influenced by which the type of dosage form of the drug. Since, injections include much variety 
of therapeutic agents. Injections are sterile, pyrogen limited, that is, bacterial endotoxin units limit, preparations intended to be 
administered parenterally. It is well recognized that the advantages of parenteral injections are immediate systemic drug availability 
and rapid onset of action. 
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INTRODUCTION 
The prime function of Research and Developments in 
pharmaceutical companies is to discover and to develop 
the new medicines. To achieve these objectives are not 
easy, in this a small percentage of the synthesized 
chemical compounds become medicines.
 1 
A generic 
drug is the same as a brand name drug in its dosage, 
safety, strength, how it taken, how it performance, 
quality and intended use.
 2 
The U.S FDA doesn’t provide regulatory formal 
definition for excipients, and then also, according to 
guidance on nonclinical safety studies, new excipients 
are inactive ingredients that added intentionally to the 
therapeutic and diagnostic products.
 3
 The desired 
product type must be determined as possible to establish 
the framework for product development, before 
formulating a drug substance into a dosage form.
 4 
Before a medicinal agent is formulated into one or more 
dosage forms, the factors to considered are such 
therapeutic matters are the nature of illness, in which the 
manner it is treated (locally or systemic action), age and 
patient’s anticipated condition. 4 The drug that we need 
should be most convenient and in proper form then only 
it reaches to the desired site of action. This is greatly 
influenced by which the type of dosage form of the 
drug. 
An ideal dosage form should be:- 
 It should be safe and easy to administer. 
 It should be easy to handle. 
 It should be easy to produce and manufacture 
 Provide high patient compliance. 
 Should be physically and chemically stable. 
 It should maintain its therapeutic activity 
throughout the shelf life.
5
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INJECTABLE SOLUTION 
Injections include much variety of therapeutic agents. In 
USP more than 400 injections products are listed.
 6 
The 
dosage forms that conveying the drug by means of the 
injection through skin or the mucous membranes.
 7 
Some 
medicines cannot be given by oral due chemical action 
of enzymes.
 8 
The most convenient and simplest form of an injectable 
product is an isotonic aqueous solution, which have the 
pH close to that of blood and the body tissues (pH 7.4).
9 
Injections that prepared in containers, antimicrobial 
agents also will add. These are intended to suppress the 
growth of micro-organisms accidentally inoculated into 
the solution.
 10
 Aqueous solutions which given through 
intramuscularly, the release of drug may be controlled 
by:  
i. Increasing the vehicle viscosity by using MC, 
CMC, or PVP and thus decreasing the molecular 
diffusion and localizing the injected drug. 
ii. Formation of complex with macromolecules like 
MC, CMC, or PVP from which the drug dissociates 
at controlled rate.
11
 
 
        Figure 1: An injectable solution 
Guiding principles for simple parenteral solutions 
Selection of injectable volume 
Pharmacopoeias classify the injection into types:- 
 Small-volume parenterals: These are usually 100ml 
or less. Depends on the intended use these are 
packaged in different ways.
12
 
 Large-volume parenterals: a single dose injection 
which intended for IV use and is packaged in 
containers, containing more than 100 ml.  
13
 
SVPs are usually given rapidly in small volume are 
called as a bolus. In LVPs also they added like 5% 
dextrose and 0.9 %sodium chloride injection or infusion 
is administered through IV infusion. Based on the 
pharmacokinetics of the drug the bolus or infusions are 
selected. A bolus administration is preferred for 
intramuscular or subcutaneous injections. Subcutaneous 
route is used if the injection volume is less than 1- 1.5 
mL and through intramuscular route usually no more 
than 2 mL.  In the formulation of a solution product, the 
main step is to select the administration volume and 
concentration.
 14 
pH and Tonicity requirements 
pH considerations 
The generation of pH/stability and pH/ solubility 
profiles is the main step in the selection of pH in a 
formulation. For the maximum physiological 
acceptability, the target pH is approximately pH 7.4.  
When the dosing through IV route, a wide pH range can 
be tolerated and a rapid dilution wit blood also can be 
achieve. pH value ranging from 2 to 12 can be tolerated 
in these situations when intramuscular administration is 
uses the dilution rate is slower and it is further decreases 
when the subcutaneous route is administered. 
Tolerability of a formulation depends on its buffering 
capacity.
 14 
  Table 1: Buffers used in the approved parenteral 
products 
Buffer pH Range 
Acetate 3.8 -5.8 
Ammonium 8.25 – 10.25 
Ascorbate  3.0 -5.0  
Benzoate 6.0 – 7.0 
Bicarbonate 4.0 – 11.0 
Citrate 2.1 – 6.2 
Diethanolamine 8.0 – 10.0  
Tromethamine (TRIS, THAM) 7.1 – 9.1 
 
Tonicity consideration   
All parenteral products should be isotonic, especially 
osmolarities should target between 280 and 290 
mOsm/L during a formulation. For LVPs isotonicity is 
very essential. Either the rapid dilution with blood that 
will occur after injection or prior to administration the 
product itself diluted with an LVP, a wider range of 
osmolarities can be tolerated in SVPs. For hypotonic 
solutions hypertonic solutions are preferred since the 
risk of haemolysis associated with the hypotonic 
solution. By the use of excipients the hypotonic 
solutions are avoided, since the sodium chloride to raise 
the osmolality. To avoid the tissue damage parenteral 
formulations should be isotonic with human plasma.
 14-15
 
Choice of excipients 
In pharmaceutical products the formulations should 
developed by using excipients. In parenteral products 
the quality, particularly in microbial terms of excipients 
should be considered necessarily. The injectable grades 
are usually used for parenteral excipients which have 
strict bio burden and endotoxin limits. The excipients 
have pharmacopoeial grade also acceptable. But this is 
usually to apply In-House microbiological specification 
limits.
 14 
The integral part of pharmaceutical products 
development is excipients, to achieve the desired 
product profile (stability and efficacy).
 15 
Excipients are 
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important to assure safety (antimicrobial preservatives), 
to minimize pain and irritation on injection, and to 
control or prolonged drug delivery.
 16 
General guidance for developing formulations of 
parenteral drugs
 
The following factors should follow, when a drug is 
given through parenterally rather than orally: 
i. The onset of action of drug is mostly more rapid 
but the duration is short. 
ii. Since the drug potency tends not to alter 
immediately by the liver or stomach, so the 
dosage form is often smaller. 
iii. The cost for the therapy is higher.17 
Pharmacokinetics of the drug: 
The absorption rate for routes of administration other 
than intravenous or intra-arterial, distribution, 
metabolism and excretion of drugs have effect on route 
of administration that selected, based on the type of 
formulation. For example: a drug having a rapid 
pharmacokinetic profile, there is need of development of 
modified release dosage formulations. Pharmacokinetics 
also affects the drug dose and the dosage regimen.
 18
 
Drug solubility: 
The formulation must contain a co-solvent or a solute 
which sufficiently increases and maintains the drug in 
solution, if the drug is insufficiently soluble in the water 
at the dosage required. Solubility is the major factor that 
gives the concentration in the dosage form. A dispersed 
system dosage form developed, when simple 
formulation additives do not result in the solution.
 18
 
Drug stability: 
If the drug possesses significant degradation problems in 
the solution, then freeze dried or sterile solid dosage 
form should be developed. Sometimes drug 
concentration affects the stability in turn, affect size and 
the packaging system used also. Stability determines the 
storage conditions since it indicates the drug expiration 
date.
 18
 
Advantages of parenteral products: 
 These are useful in :- 
 Unconscious patients. 
 Uncooperative and unreliable patients. 
 Onset of action of drugs is faster; hence it is 
suitable for emergency. 
 Patients with vomiting and diarrhea. 
 These are suitable for irritant drugs and drugs with 
high first pass metabolism. 
 Drugs are not absorbed orally. 
 Drugs destroyed by digestive juices. 
 
 
Disadvantages 
 Parenteral preparations should be sterile and 
expensive. 
 They require aseptic conditions. 
 Cost  
 They can’t easily self- administrated. 
 Causes local tissue injury to nerves, vessels, etc. 
Parenteral product formulation depends upon the 
understanding of several factors that dictate the choice 
of formulation and dosage form.
 19 
METHODOLOGY 
Development of parenteral products 
Based on the requirements of sterility of the finished 
product parenteral products manufacturing process 
considered.      
 
Figure 2: Production of parenterals 
1. Filtration 
If the product is a solution, after its compounding, it 
should filter. Filtration process is employed for to clarify 
a solution and removing particulate matter down to 
0.2μm in size will eliminate the micro-organisms. It is 
accomplished by cold sterilization. Filters mainly 
functions by: 
 Sieving or screening: 
      The particles are retained on the surface of the filter 
by sieving  
 Entrapment or impaction: 
 If the particles smaller than the dimensions of the pore, 
they impact on the surface of the pore. 
 Electrostatic attraction 
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Opposite charged particle to that of the surface of the 
filter pore to be adsorbed on the surface. 
Membrane filters are used for parenteral preparations 
because they have high effective in particle- retention, 
non-shedding property, non- reactivity and have 
disposable characteristics also. The most common 
membranes are made up of cellulose esters, nylon, 
polycarbonate, PVDF, and Teflon. Membrane filters are 
disposable type and can be discarded after use. It should 
clean thoroughly while using. Most pharmaceutical 
industries that preparing parenterals uses 0.2 μm 
membrane filter.
 19 
2. Filling 
The solutions which sterilized through filtration are to 
be filled under the aseptic conditions. During the filling 
of product to the containers, should be for the 
prevention of contamination, especially the product is 
sterilized by the filtration and will not be sterilized in to 
the final container. The second one is called as aseptic 
fill and by using media fills it is validated. A liquid is 
more easily exposed uniformly into the container having 
the narrow mouth than is used for solid. Liquids which 
are mobile are easier to transfer and subdivide than 
viscous or sticky fluids, since these require heavy-duty 
machinery for the rapid production filling.
 19-20
 
Liquid 
The filling of liquids into containers with high accuracy 
involves mainly three methods 
 Volumetric filling 
 Time/pressure filling 
 Net weight filling 
Volumetric filling machines have pistons or peristaltic 
pumps. These are most common used method. Time-
pressure filling is used for filling of sterile liquids. A 
filling system is connected by a production tank that 
equipped with a pressure sensor. The sensor is used for 
the measurement of pressure and transmits values PLC 
system that controls the product flow from the tank to 
the filling manifold. The product is driven by using 
pressure mainly uses nitrogen with no pump 
mechanism. Time/pressure filling is preferable usually 
with the proteins that are sensitive to shear forces.
 19
 
3. Sealing 
The filled containers should be filled as soon as possible 
to prevent the contents being contaminated. It represents 
the final aseptic procedure.
 20 
Ampoules 
Sealing of ampoules are done by melting of the portion 
of the glass neck. There are two types of sealing:- 
 Pull –seals 
 Tip-seals (bead –seals) 
Tip seals are employed by melting the glass at the tip of 
the ampoule neck to form a bead like and close the 
opening. This is performed in a high temperature gas 
oxygen flame. Pull-seals are performed by heat the 
ampoule neck below the tip. The ampoule to be   seal is 
rotated in the flame from a single burner. The tip is 
grasped and then pulled quickly from the ampoule body, 
when the glass is softens. Pull sealing process is slower 
one, but the sealing done by this is more secure than that 
of tip-sealing.   
Vials and bottles 
By closing the opening using the rubber closure 
(stopper) the glass or the plastic vials are sealed 
properly. This should be done by after filling with care, 
to prevent the contamination of the contents inside. 
Increased chances for contamination are the large 
opening in the vials than the ampoules. The open 
containers must be protected from contamination, 
especially with the blanket of HEPA filtered laminar 
airflow. By using the aluminium caps the rubber 
stoppers are held in appropriate place. Rubber closures 
that uses for the intravenous administration have a 
permanent hole through the closure.
 19
 
4. Sterilization 
Sterilization of parenteral products should be done after 
sealing it to the final container that is called as terminal 
sterilization. It should done within as short time as that 
possible after the filling and sealing are fully completed. 
This is accomplished usually by the thermal process. 
Radiation sterilization also will do to the parenteral 
finished products in sometimes. The care should be 
taken in the effect of the elevated temperature on the 
stability of the products. The elevated temperature that 
required for the sterilization by thermal process is 
adversely affects in many products like both 
pharmaceutical and biological. Non thermal methods are 
used for the heat-labile products. These non thermal 
methods include filtration through the bacteria retaining 
filters. Aseptic conditions should be strictly followed for 
all operations, and then only the contamination is not 
introduced into the filtrate.  Dry-heat sterilization is 
performed for few dry solids that are not adversely 
affects by the high temperatures and that require long 
period of heating. For the sterilization of glassware and 
metal ware mostly performs the dry-heat sterilization 
process. After the sterilization process all the equipment 
will be sterile, dry and pyrogen-free.  Autoclaving 
(saturated steam under pressure) is the most common 
method used for sterilization process. It is the most 
effective sterilization method that used for the aqueous 
liquids or substances, since it can be reached or 
penetrated by the steam.
 [19]
Radiation sterilization is a 
terminal sterilization method with an ionizing radiation 
(gamma rays). There is an advantage for the applying on 
drugs in their final container, that also without any rise 
in temperature. One of the disadvantages is the possible 
formation of radiolytic products which leads to a change 
in the color and odor of the product.
 21-22
 
5. Packaging of parenterals 
 Types of containers: 
A. Glass containers 
B. Plastic containers 
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 Glass containers 
In most of the SVIs glass is used as the material choice 
for the containers. Principally glass containers are 
composed of silicon dioxide with varying amounts of 
various oxides such as potassium, sodium, calcium, 
magnesium, aluminum, boron, and iron. Silicon oxide 
tetrahedron forms the basic structural network of glass. 
Boric oxide will enter into the basic structural network 
and the other oxides do not enter into this structure.
 19
 
Table 2:  USP glass types 
Types General Description General Use 
 
I.  
 
Highly resistant borosilicate glass 
 Buffered and unbuffered aqueous solutions  
 All other uses. 
 
II.  
 
Treated soda- lime glass 
 Buffered aqueous solutions with pH below 7.0 
 Dry powders 
 Oleaginous solutions. 
 
III.  
 
Soda- lime glass 
 Dry powders 
 Oleaginous solutions 
 
      NP 
 
General purpose soda-lime glass 
 Not for parenterals. 
 For tablets, oral solutions, ointments, external liquids 
 
Plastic containers 
Sterile preparation like large-volume parenterals, 
ophthalmic solutions and mainly in small volume 
parenterals uses thermoplastic polymers as packaging 
materials. The principal advantage of plastic while 
comparing with glass, it is not breakable easily and 
reduction in weight also. In large-volume intravenous 
fluids currently uses the flexible bags of PVC (polyvinyl 
chloride) or select polyolefin. This having major 
advantage that there is no requirement of air 
interchange.
19
 
Rubber Closures 
Rubber closures are made up of using milling machines 
by multiple ingredients plasticized and mixed together at 
an elevated temperature
 19
. The allergenic proteins from 
the natural rubber vial closures or stoppers that release 
into aqueous pharmaceuticals induce some allergic 
reactions in individuals with latex allergy receiving 
medications from such vials.
23 
EVALUATION 
pH 
pH is the measure of concentration of protons (H
+
) in a 
solution that is the potential of  hydrogen. It is the 
identification of a substance how it is acidic or alkaline 
by using a scale of acidity from 0 to 14.  More the acidic 
solutions having lower pH, and more alkaline solutions 
having higher pH values.  pH value less than 7 are acids 
and pH  of greater than 7 are alkaline. The neutral 
solutions that are the substances which are not acidic or 
alkaline have a pH value of 7
24
 
Particulate matter 
In injections and parenteral infusions particulate matter 
are considered as, the mobile undissolved particles, other 
than the gas bubbles, unintentionally that present in the 
solutions. There are two procedures involved in the 
determination of particulate matter.  
Sub-visible particles  
 Method 1 (light obscuration particle count test) 
 Method 2 (microscopic particle count test) 
Injections and parenteral infusions are examined for sub-
visible particles usually method 1 is preferred mostly. 
Then also some preparations by light obscuration 
particle count test that followed by microscopic particle 
count test is necessary to test. No all parenterals are 
examined by method 1such as preparations that reduced 
clarity or increased viscosity, since these tests are carried 
out according to method 2. For example: colloids, 
emulsions. Particulate matter contamination is still 
having a potential cause to the harm patients. 
19-25
 
Sterility 
Sterility testing is to identify the presence or absence of 
viable micro-organisms in the sample.
 26 
A. Immersion (Direct inoculation) 
It requires the test article to be inoculated directly into 
test media.
 27 
B. Membrane Filtration 
It requires the test article to pass through a size 
exclusion membrane which capable of retaining micro-
organisms. Filter should be rinsed. Then the membrane 
is transferred to the test medium.
 27 
Media types: mostly used Soya-bean casein digest 
(SCD) and Fluid thioglycollate media (FTM). 
28-29 
Incubation period: all test containers should incubated 
at temperatures  as specified in the pharmacopoeial 
method , that is for each test media at least 14 days, 
depends on whether filtration or direct inoculation test is 
used.
28-29 
Stability 
Stability is defined as the capacity of a drug substance or 
drug product to remain within the established 
specifications to maintain its identity, strength, quality 
and purity throughout the retest or expiration dating 
period. The objective of stability study is to determine 
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the shelf life, namely the time period of storage at a 
specified condition within which the drug product still 
meets its established specifications. Stability testing also 
gives information about drug vulnerability to degrade by 
oxidation, hydrolysis, isomerisation, polymerization, 
decarboxylation, moisture, heat and light. Stability study 
is performed for specific time at specific environmental 
condition according to ICH guideline.
 30 
DISCUSSION 
This report presents a summary of pharmaceutical 
development of an injectable solution. It emphasizes a 
science and risk based approach to product and process 
development and presents findings as a knowledge- 
based report, where relevant, supporting data have been 
summarized in appropriate dosage form or illustrations. 
Formulation development involved the use of prior 
knowledge and structured experimentation to investigate 
the relationship between formulation component levels, 
API attributes and the drug product quality attributes. 
Using prior knowledge the material attributes and 
process parameters, which could have an impact upon 
final product quality, were identified. 
The liquid injection tested for its sterility, Bacterial 
endotoxin test. The tests passes by obtaining a sterile 
solution and the bacterial endotoxin test obtained within 
the specification limits. .  Particulate matter count 
assessed by using light obscuration method and the test 
passes for the solution by obtaining free from the foreign 
particles. 
CONCLUSION 
The most effective route for the delivery of the active 
pharmaceutical substances is the parenteral rout of 
administration, prescribed to unconscious patients. The 
present article describes that design, principles and 
manufacturing of sterile products. Parenteral 
preparations are the pyrogen free liquids, which 
manufactured and stored accordingly to cGMP 
guidelines. An excellent parenteral product will require 
proper area, good environmental control and personnel 
observation, to attain their described therapeutic effect. 
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